查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1454740

結構心臟器械市場- 按產品（心臟瓣膜裝置、封堵器和輸送系統、瓣環成形術環）、按程序（更換、修復）、最終用途（醫院、ASC、心導管實驗室） - 全球預測， 2024 年- 2032 年

Structural Heart Devices Market - By Product (Heart Valve Devices, Occluders & Delivery Systems, Annuloplasty Rings), By Procedure (Replacement, Repair), By End-use (Hospitals, ASC, Cardiac Catheterization Labs) - Global Forecast, 2024 - 2032
出版日期: | 出版商: Global Market Insights Inc. | 英文 220 Pages | 商品交期: 2-3個工作天內

價格
簡介目錄

由於應用範圍的擴大和新產品的不斷開發，結構心臟器材市場規模預計在 2024 年至 2032 年間以 8.8% 的CAGR擴大。

除了瓣膜置換和修復等傳統手術之外，結構性心臟裝置也用於治療多種疾病，包括心房中隔缺損 (ASD)、卵圓孔未閉 (PFO) 和左心耳封堵術 (LAAC)。此外，設備技術的不斷進步正在導致新型材料、改進的輸送系統和增強的成像技術的開發。例如，2024 年 3 月，雅培在美國推出了最新版本的 Navitor 心臟瓣膜技術，與上一型號相比進行了多項改進。此類新產品的開發旨在提高功效、安全性和結果，推動了全球對結構心臟設備的需求。

該行業分為產品、程序、最終用途和地區。

根據產品，瓣環成形環領域的市佔率預計將從 2024 年至 2032 年以 9.1% 的CAGR獲得顯著成長。這些環在心臟瓣膜修復和置換手術中發揮著至關重要的作用，特別是在二尖瓣和三尖瓣手術中。瓣膜性心臟病的盛行率不斷上升，加上微創手術技術的日益普及，將推動對瓣環成形術環的需求，為心臟瓣膜提供結構支撐，以改善其功能和耐用性。此外，環設計、材料和技術的進步也推動了該領域的成長。

就最終用途而言，心導管實驗室領域的結構性心臟器械市場在2023 年產生了可觀的收入，預計到2032 年成長率將達到9.1%。心導管實驗室處於結構性心臟病微創手術的前沿，如經導管主動脈瓣置換術（TAVR）和經導管二尖瓣修復術（TMVR）。心血管疾病的盛行率不斷上升以及對微創治療方案的偏好正在推動這些專業設施對結構性心臟設備的需求。

考慮到區域格局，在心血管疾病盛行率上升、人口老化和生活方式改變的推動下，亞太地區結構心臟器械產業2024年至2032年的CAGR將達到9.9%。此外，經濟狀況的改善和醫療保健支出的增加正在促進該地區先進心臟手術的採用。因此，中國、印度、日本和韓國等國家正成為結構性心臟器械製造商的重要中心。醫療保健基礎設施的進步、先進醫療技術的普及以及熟練醫療保健專業人員數量的不斷增加正在進一步推動區域市場的擴張。

目錄

第 1 章：方法與範圍

第 2 章：執行摘要

第 3 章：產業洞察

  • 產業生態系統分析
  • 產業影響力
    • 成長動力
      • 心血管疾病負擔日益加重
      • 技術進步
      • 有利的報銷方案
      • 對微創手術的偏好不斷上升
    • 產業陷阱與挑戰
      • 嚴格的監理政策
      • 潛在的併發症和不良事件
  • 成長潛力分析
  • 波特的分析
  • PESTEL分析
  • 2023 年定價分析
  • 報銷場景
  • 監管環境
  • 技術景觀
  • 未來市場趨勢
  • 缺口分析

第 4 章：競爭格局

  • 介紹
  • 公司矩陣分析
  • 公司市佔率分析
  • 競爭定位矩陣
  • 戰略儀表板

第 5 章：市場估計與預測：按產品分類，2018 年 - 2032 年

  • 主要趨勢
  • 心臟瓣膜裝置
    • 外科心臟瓣膜
    • 經導管心臟瓣膜
  • 瓣環成形術環
  • 封堵器和輸送系統
  • 其他產品

第 6 章：市場估計與預測：按程序，2018 年 - 2032 年

  • 主要趨勢
  • 更換程序
    • 主動脈瓣置換手術 (SAVR)
    • 經導管主動脈瓣置換術 (TAVR)
    • 經導管二尖瓣置換術 (TMVR)
    • 其他更換流程
  • 維修程序
    • 左心耳封堵術 (LAAC)
    • 經導管二尖瓣修復術 (TMVr)
    • 經導管三尖瓣修復術 (TTVR)
    • 瓣膜成形術
    • 其他維修程序

第 7 章：市場估計與預測：按最終用途，2018 - 2032 年

  • 主要趨勢
  • 醫院
  • 門診手術中心
  • 心導管實驗室
  • 其他最終用戶

第 8 章：市場估計與預測：按地區分類，2018 年 - 2032 年

  • 主要趨勢
  • 北美洲
    • 美國
    • 加拿大
  • 歐洲
    • 德國
    • 英國
    • 法國
    • 西班牙
    • 義大利
    • 歐洲其他地區
  • 亞太地區
    • 中國
    • 日本
    • 印度
    • 澳洲
    • 韓國
    • 亞太地區其他地區
  • 拉丁美洲
    • 巴西
    • 墨西哥
    • 阿根廷
    • 拉丁美洲其他地區
  • 中東和非洲
    • 南非
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國
    • 中東和非洲其他地區

第 9 章：公司簡介

  • Abbott Laboratories
  • AtriCure, Inc.
  • Biomerics, LLC
  • Boston Scientific Corporation
  • Braile Biomedica
  • Cryolife Inc.
  • Edwards Lifesciences Corporation
  • JenaValve Technology, Inc.
  • Lepu Medical Technology(Beijing)Co.,Ltd.
  • LivaNova PLC
  • Medtronic plc
  • NuMed Inc.
簡介目錄
Product Code: 3231

Structural Heart Devices Market size is poised to expand at 8.8% CAGR between 2024 and 2032 due to the expanding application scope and continuous new product developments.

Beyond traditional procedures, such as valve replacements and repairs, structural heart devices are used for treating a wide range of conditions, including atrial septal defects (ASDs), patent foramen ovale (PFO), and left atrial appendage closures (LAAC). Moreover, the ongoing advancements in device technologies are leading to the development of novel materials, improved delivery systems, and enhanced imaging techniques. For instance, in March 2024, Abbott introduced the most recent version of its Navitor heart valve technology in the U.S. with several improvements over the last model. Such new product developments to offer improved efficacy, safety, and outcomes are fueling the demand for structural heart devices worldwide.

The industry is segmented into product, procedure, end-use, and region.

Based on product, the market share from the annuloplasty rings segment is projected to gain significant traction at 9.1% CAGR from 2024-2032. These rings play a vital role in surgical procedures for heart valve repair and replacement, particularly in mitral and tricuspid valve surgeries. The rising prevalence of valvular heart diseases coupled with the increasing adoption of minimally invasive surgical techniques will drive the demand for annuloplasty rings to provide structural support to the heart valves for improving their function and durability. Furthermore, advancements in ring designs, materials, and technologies are also propelling the segment growth.

With respect to end-use, the structural heart devices market from the cardiac catheterization labs segment generated considerable revenue in 2023 and is estimated to witness 9.1% growth rate through 2032. Cardiac catheterization labs are at the forefront of minimally invasive procedures for structural heart conditions, such as transcatheter aortic valve replacement (TAVR) and transcatheter mitral valve repair (TMVR). The increasing prevalence of cardiovascular diseases and the preference for less invasive treatment options are fueling the demand for structural heart devices in these specialized facilities.

Given the regional landscape, the Asia Pacific structural heart devices industry is set to exhibit 9.9% CAGR from 2024-2032 driven by the rising prevalence of cardiovascular diseases, coupled with the aging population and changing lifestyles. Moreover, the improving economic conditions and increasing healthcare expenditure are facilitating the adoption of advanced cardiac procedures across the region. As a result, countries including China, India, Japan, and South Korea are becoming significant hubs for structural heart device manufacturers. Advancements in healthcare infrastructure, access to sophisticated medical technologies, and the growing number of skilled healthcare professionals are further driving the regional market expansion.

Table of Contents

Chapter 1 Methodology & Scope

  • 1.1 Market scope & definition
  • 1.2 Base estimates & calculations
  • 1.3 Data collection
  • 1.4 Forecast calculations
  • 1.5 Data validation
  • 1.6 Data sources
    • 1.6.1 Primary
    • 1.6.2 Secondary
      • 1.6.2.1 Paid sources
      • 1.6.2.2 Unpaid sources

Chapter 2 Executive Summary

  • 2.1 Industry 360 degree synopsis

Chapter 3 Industry Insights

  • 3.1 Industry ecosystem analysis
  • 3.2 Industry impact forces
    • 3.2.1 Growth drivers
      • 3.2.1.1 Growing burden of cardiovascular diseases
      • 3.2.1.2 Technological advancements
      • 3.2.1.3 Favorable reimbursement scenario
      • 3.2.1.4 Rising preference for minimally invasive procedures
    • 3.2.2 Industry pitfalls & challenges
      • 3.2.2.1 Stringent regulatory policies
      • 3.2.2.2 Potential complications and adverse events
  • 3.3 Growth potential analysis
  • 3.4 Porter's analysis
    • 3.4.1 Supplier power
    • 3.4.2 Buyer power
    • 3.4.3 Threat of new entrants
    • 3.4.4 Threat of substitutes
    • 3.4.5 Industry rivalry
  • 3.5 PESTEL analysis
  • 3.6 Pricing analysis, 2023
  • 3.7 Reimbursement scenario
  • 3.8 Regulatory landscape
  • 3.9 Technological landscape
  • 3.10 Future market trends
  • 3.11 GAP analysis

Chapter 4 Competitive Landscape, 2023

  • 4.1 Introduction
  • 4.2 Company matrix analysis
  • 4.3 Company market share analysis
  • 4.4 Competitive positioning matrix
  • 4.5 Strategy dashboard

Chapter 5 Market Estimates and Forecast, By Product, 2018 - 2032 ($ Mn)

  • 5.1 Key trends
  • 5.2 Heart valve devices
    • 5.2.1 Surgical heart valves
    • 5.2.2 Transcatheter heart valves
  • 5.3 Annuloplasty rings
  • 5.4 Occluders & delivery systems
  • 5.5 Other products

Chapter 6 Market Estimates and Forecast, By Procedure, 2018 - 2032 ($ Mn)

  • 6.1 Key trends
  • 6.2 Replacement procedures
    • 6.2.1 Surgical aortic valve replacement (SAVR)
    • 6.2.2 Transcatheter aortic valve replacement (TAVR)
    • 6.2.3 Transcatheter mitral valve replacement (TMVR)
    • 6.2.4 Other replacement procedures
  • 6.3 Repair procedures
    • 6.3.1 Left atrial appendage closure (LAAC)
    • 6.3.2 Transcatheter mitral valve repair (TMVr)
    • 6.3.3 Transcatheter tricuspid valve repair (TTVr)
    • 6.3.4 Valvuloplasty
    • 6.3.5 Other repair procedures

Chapter 7 Market Estimates and Forecast, By End-Use, 2018 - 2032 ($ Mn)

  • 7.1 Key trends
  • 7.2 Hospitals
  • 7.3 Ambulatory surgical centers
  • 7.4 Cardiac catheterization labs
  • 7.5 Other end-users

Chapter 8 Market Estimates and Forecast, By Region, 2018 - 2032 ($ Mn)

  • 8.1 Key trends
  • 8.2 North America
    • 8.2.1 U.S.
    • 8.2.2 Canada
  • 8.3 Europe
    • 8.3.1 Germany
    • 8.3.2 UK
    • 8.3.3 France
    • 8.3.4 Spain
    • 8.3.5 Italy
    • 8.3.6 Rest of Europe
  • 8.4 Asia Pacific
    • 8.4.1 China
    • 8.4.2 Japan
    • 8.4.3 India
    • 8.4.4 Australia
    • 8.4.5 South Korea
    • 8.4.6 Rest of Asia Pacific
  • 8.5 Latin America
    • 8.5.1 Brazil
    • 8.5.2 Mexico
    • 8.5.3 Argentina
    • 8.5.4 Rest of Latin America
  • 8.6 Middle East and Africa
    • 8.6.1 South Africa
    • 8.6.2 Saudi Arabia
    • 8.6.3 UAE
    • 8.6.4 Rest of Middle East and Africa

Chapter 9 Company Profiles

  • 9.1 Abbott Laboratories
  • 9.2 AtriCure, Inc.
  • 9.3 Biomerics, LLC
  • 9.4 Boston Scientific Corporation
  • 9.5 Braile Biomedica
  • 9.6 Cryolife Inc.
  • 9.7 Edwards Lifesciences Corporation
  • 9.8 JenaValve Technology, Inc.
  • 9.9 Lepu Medical Technology(Beijing)Co.,Ltd.
  • 9.10 LivaNova PLC
  • 9.11 Medtronic plc
  • 9.12 NuMed Inc.